
Coherus BioSciences CHRS
$ 0.37
-5.13%
Coherus BioSciences Book Value | CHRS
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Coherus BioSciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61 M | -132 M | -193 M | -137 M | 97.7 M | 281 M | 105 M | -38.6 M | 30.5 M | 19.4 M | -6.93 M | 66.8 M | -42.4 M | 9.19 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 281 M | -193 M | 8.57 M |
Quarterly Book Value Coherus BioSciences
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.2 M | 60.8 M | 78.6 M | 61 M | 87.8 M | 120 M | -183 M | -132 M | -88 M | -84.1 M | -81.8 M | -193 M | -134 M | -175 M | -197 M | -137 M | -97.1 M | -22.6 M | 12.6 M | 97.7 M | 131 M | 156 M | 128 M | 281 M | 256 M | 213 M | 157 M | 105 M | 56 M | -3.98 M | -38.5 M | -38.6 M | 12.4 M | 61.8 M | -3.09 M | 30.5 M | 54.9 M | 30.9 M | 77 M | 19.4 M | 31.7 M | -61.9 M | -66.9 M | -6.93 M | 40 M | 96.4 M | 38 M | 66.8 M | 9.18 M | 66.8 M | 66.8 M | -42.4 M | -42.4 M | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 281 M | -197 M | 17 M |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Shattuck Labs
STTK
|
82.4 M | $ 4.49 | -1.43 % | $ 312 M | ||
|
Silence Therapeutics plc
SLN
|
9.06 M | $ 19.81 | 0.08 % | $ 2.81 B | ||
|
Soligenix
SNGX
|
5.29 M | $ 0.22 | -8.25 % | $ 1.14 M | ||
|
Sanofi
SNY
|
127 B | $ 46.51 | 0.97 % | $ 56.8 B | ||
|
Spruce Biosciences
SPRB
|
42.5 M | $ 38.02 | -6.11 % | $ 29.1 M | ||
|
Spero Therapeutics
SPRO
|
59 M | $ 0.74 | -10.95 % | $ 41.5 M | ||
|
Sarepta Therapeutics
SRPT
|
1.14 B | $ 13.34 | -5.86 % | $ 1.34 B | ||
|
Savara
SVRA
|
203 M | $ 4.28 | -17.95 % | $ 952 M | ||
|
Teligent, Inc.
TLGT
|
5.17 B | - | -13.85 % | $ 16.1 M | ||
|
Viela Bio, Inc.
VIE
|
424 M | - | - | $ 2.91 B | ||
|
Sutro Biopharma
STRO
|
-132 M | $ 8.6 | -1.38 % | $ 73.1 M | ||
|
Tarsus Pharmaceuticals
TARS
|
343 M | $ 72.94 | -6.09 % | $ 3.05 B | ||
|
Supernus Pharmaceuticals
SUPN
|
1.06 B | $ 36.28 | 1.88 % | $ 2.05 B | ||
|
TG Therapeutics
TGTX
|
648 M | $ 63.39 | -2.3 % | $ 9.15 B | ||
|
Aphria Inc.
APHA
|
6.38 B | - | -0.45 % | $ 4.87 B | ||
|
Viridian Therapeutics
VRDN
|
722 M | $ 29.91 | -4.87 % | $ 3.05 B | ||
|
Trevi Therapeutics
TRVI
|
183 M | $ 13.35 | -2.73 % | $ 1.8 B | ||
|
Aerpio Pharmaceuticals, Inc.
ARPO
|
371 M | - | -0.90 % | $ 104 M | ||
|
Chiasma, Inc.
CHMA
|
3.57 B | - | -6.00 % | $ 238 M | ||
|
vTv Therapeutics
VTVT
|
64.4 M | $ 16.0 | -2.2 % | $ 64.2 M | ||
|
Adamas Pharmaceuticals, Inc.
ADMS
|
25.9 M | - | - | $ 376 M | ||
|
Cellect Biotechnology Ltd.
APOP
|
1.02 B | - | 0.38 % | $ 12.9 M | ||
|
Xenon Pharmaceuticals
XENE
|
582 M | $ 36.89 | -1.78 % | $ 2.92 B | ||
|
Xeris Pharmaceuticals
XERS
|
13.7 M | $ 16.95 | 2.02 % | $ 2.72 B | ||
|
AzurRx BioPharma, Inc.
AZRX
|
27.2 B | - | 2.07 % | $ 34.4 M | ||
|
X4 Pharmaceuticals
XFOR
|
186 M | $ 3.01 | 1.69 % | $ 127 M | ||
|
Cerecor Inc.
CERC
|
1.53 B | - | -1.68 % | $ 283 M | ||
|
Constellation Pharmaceuticals, Inc.
CNST
|
6.62 M | - | - | $ 1.63 B | ||
|
Auris Medical Holding Ltd.
EARS
|
154 M | - | -1.77 % | $ 39.2 M | ||
|
Dicerna Pharmaceuticals, Inc.
DRNA
|
101 M | - | 0.34 % | $ 2.98 B | ||
|
ERYTECH Pharma S.A.
ERYP
|
45.8 M | - | 1.3 % | $ 27.7 M | ||
|
GW Pharmaceuticals plc
GWPH
|
23 M | - | - | $ 6.81 B | ||
|
22nd Century Group
XXII
|
18.5 M | $ 0.32 | -19.83 % | $ 58.9 K | ||
|
Kadmon Holdings, Inc.
KDMN
|
8.24 B | - | - | $ 1.7 B | ||
|
Liminal BioSciences
LMNL
|
36.2 M | - | - | $ 256 M | ||
|
argenx SE
ARGX
|
7.32 B | $ 926.42 | -1.66 % | $ 56.8 B | ||
|
Tonix Pharmaceuticals Holding Corp.
TNXP
|
245 M | $ 2.33 | -7.25 % | $ 19.8 M | ||
|
Zai Lab Limited
ZLAB
|
716 M | $ 21.01 | -4.16 % | $ 23 B | ||
|
Neos Therapeutics, Inc.
NEOS
|
19.8 M | - | -2.54 % | $ 57.2 M | ||
|
Zentalis Pharmaceuticals
ZNTL
|
216 M | $ 1.37 | 0.74 % | $ 98.5 M | ||
|
Zoetis
ZTS
|
3.33 B | $ 78.81 | -2.47 % | $ 34.9 B | ||
|
Odonate Therapeutics, Inc.
ODT
|
1.44 B | - | -3.18 % | $ 58.5 M | ||
|
Orphazyme A/S
ORPH
|
148 M | - | -2.25 % | $ 31.3 M | ||
|
Osmotica Pharmaceuticals plc
OSMT
|
6.72 B | - | -10.74 % | $ 89.9 M | ||
|
Pandion Therapeutics, Inc.
PAND
|
1.77 B | - | - | $ 1.77 B | ||
|
Xenetic Biosciences
XBIO
|
7.4 M | $ 1.47 | -4.55 % | $ 2.5 M | ||
|
Translate Bio, Inc.
TBIO
|
493 M | - | - | $ 2.81 B | ||
|
Trillium Therapeutics Inc.
TRIL
|
-2.22 M | - | - | $ 1.94 B | ||
|
Urovant Sciences Ltd.
UROV
|
5.99 B | - | - | $ 532 M | ||
|
Acceleron Pharma Inc.
XLRN
|
362 M | - | - | $ 10.9 B |